RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Hepion Pharmaceuticals Stock

Hepion Pharmaceuticals Liabilities 2024

Hepion Pharmaceuticals Liabilities

10.81 M USD

Ticker

HEPA

ISIN

US4268971045

WKN

A2PN6W

In 2024, Hepion Pharmaceuticals's total liabilities amounted to 10.81 M USD, a 3.98% difference from the 10.4 M USD total liabilities in the previous year.

Hepion Pharmaceuticals Aktienanalyse

What does Hepion Pharmaceuticals do?

Hepion Pharmaceuticals Inc. is a biopharmaceutical company focused on researching and developing therapeutics for the treatment of liver diseases. The company was founded in 2013 and is headquartered in Edison, New Jersey. The history of Hepion Pharmaceuticals Inc. began with the discovery of a new approach to treating liver diseases. Researchers found that small molecules targeting specific cells in the liver could have a positive effect on liver function. Hepion used this discovery as a starting point for developing new drugs to treat liver diseases. Hepion Pharmaceuticals Inc.'s business model is based on the development and marketing of innovative therapeutics for a variety of liver diseases, including fatty liver disease, alcoholic liver disease, non-alcoholic steatohepatitis (NASH), liver fibrosis, liver cirrhosis, and liver cancer. Hepion Pharmaceuticals has several divisions, all focused on the development of therapeutics for liver diseases. The primary division is research and development, which focuses on identifying and developing new drugs for the liver. Another important division is clinical development, where the drugs are tested and validated in clinical trials. The third division is marketing, where the therapeutics are marketed and sold. Hepion Pharmaceuticals Inc. currently offers two products. The first product is CRV431, a top-notch inhibitor of cytokine-mediated signaling. It is an orally administered drug specifically developed for the treatment of liver fibrosis. CRV431 aims to inhibit cytokine-mediated signaling responsible for fibrosis formation. The second product is an idiosyncratic database marketed under the name AI-Enabler. It is touted by the company as a groundbreaking tool for more precise medicine and research in support of drug development work. Overall, Hepion Pharmaceuticals Inc. is a promising biopharma company with a clear focus on developing new drugs for the treatment of liver diseases. With its innovative products and expertise in research and development, the company collaborates closely with partners from the scientific, industrial, and governmental sectors. It is hoped that this company will make further pioneering discoveries in the future and contribute to the benefit of human health. Hepion Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Hepion Pharmaceuticals's Liabilities

Hepion Pharmaceuticals's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Hepion Pharmaceuticals's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Hepion Pharmaceuticals's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Hepion Pharmaceuticals's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Hepion Pharmaceuticals’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Hepion Pharmaceuticals stock

What is the level of liabilities of Hepion Pharmaceuticals this year?

Hepion Pharmaceuticals has a debt balance of 10.81 M USD this year.

What were the liabilities of Hepion Pharmaceuticals compared to the previous year?

The liabilities of Hepion Pharmaceuticals have increased by 3.98% increased compared to the previous year.

What are the consequences of high debt for investors of Hepion Pharmaceuticals?

High liabilities can pose a risk for investors of Hepion Pharmaceuticals, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Hepion Pharmaceuticals?

Low liabilities mean that Hepion Pharmaceuticals has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Hepion Pharmaceuticals affect the company?

An increase in liabilities of Hepion Pharmaceuticals can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Hepion Pharmaceuticals affect the company?

A decrease in the liabilities of Hepion Pharmaceuticals can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Hepion Pharmaceuticals?

Some factors that can influence the liabilities of Hepion Pharmaceuticals include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Hepion Pharmaceuticals so important for investors?

The liabilities of Hepion Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Hepion Pharmaceuticals take to modify the liabilities?

To change its liabilities, Hepion Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Hepion Pharmaceuticals pay?

Over the past 12 months, Hepion Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Hepion Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Hepion Pharmaceuticals?

The current dividend yield of Hepion Pharmaceuticals is .

When does Hepion Pharmaceuticals pay dividends?

Hepion Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Hepion Pharmaceuticals?

Hepion Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Hepion Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Hepion Pharmaceuticals located?

Hepion Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hepion Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hepion Pharmaceuticals from 11/16/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/16/2024.

When did Hepion Pharmaceuticals pay the last dividend?

The last dividend was paid out on 11/16/2024.

What was the dividend of Hepion Pharmaceuticals in the year 2023?

In the year 2023, Hepion Pharmaceuticals distributed 0 USD as dividends.

In which currency does Hepion Pharmaceuticals pay out the dividend?

The dividends of Hepion Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Hepion Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Hepion Pharmaceuticals

Our stock analysis for Hepion Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hepion Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.